| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50 - 1/250 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | p40; RAB9p40; RABEPK; RGD1310612; RP11 65N13.1; RP23-446N16.2;;RabEPK |
| WB Predicted band size | Calculated MW: 41 kDa ; Observed MW: 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human RabEPK |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于VIMP(VCP-interacting membrane protein)抗体的模拟参考文献示例(注：部分文献信息为示例性概括，建议通过学术数据库获取具体文献)：
---
1. **文献名称**: *"VCP-interacting membrane protein (VIMP) links the endoplasmic reticulum stress response to neuronal degeneration"*
**作者**: Hirabayashi M., et al.
**摘要**: 研究揭示了VIMP在内质网应激反应中的作用，通过抗体标记技术发现其与神经退行性疾病中异常蛋白聚集的关联，提示VIMP可能作为ALS等疾病的治疗靶点。
2. **文献名称**: *"Role of VIMP in ER-associated degradation: Insights from antibody-mediated functional inhibition"*
**作者**: Ballar P., Fang S.
**摘要**: 利用特异性抗体阻断VIMP功能，证明其在ERAD途径中协助VCP(p97)转运错误折叠蛋白至胞质蛋白酶体，为病理条件下蛋白质质量控制机制提供依据。
3. **文献名称**: *"Antibody-based profiling of VIMP expression in inclusion body myopathy"*
**作者**: Kimura T., et al.
**摘要**: 通过免疫组化分析VIMP抗体在包涵体肌病患者的肌肉组织中的表达模式，发现其与自噬标志物共定位，提示VIMP在肌病病理中的双重调控作用。
4. **文献名称**: *"Structural characterization of VIMP using monoclonal antibodies: Implications for membrane protein topology"*
**作者**: Yamanaka T., et al.
**摘要**: 基于单克隆抗体的表位定位研究，解析了VIMP的跨膜结构域，并验证其在内质网膜上的定向分布，为后续功能研究提供结构基础。
---
**备注**：实际文献需通过PubMed、Google Scholar等平台以关键词“VIMP antibody”“VCP-interacting membrane protein”等检索，并筛选与实验应用或疾病机制相关的研究。
**Background of VIMP Antibody**
The VCP-interacting membrane protein (VIMP), also known as SEL1L3 or DERLIN1. is a key component of the endoplasmic reticulum (ER)-associated degradation (ERAD) machinery. It was initially identified as a binding partner of valosin-containing protein (VCP/p97), an ATPase critical for extracting misfolded proteins from the ER lumen during ERAD. VIMP acts as a scaffold, linking the ERAD ubiquitin ligase complex (e.g., HRD1-SYVN1) to VCP/p97. facilitating the retrotranslocation and proteasomal degradation of aberrant proteins.
VIMP is implicated in maintaining ER homeostasis by mediating the clearance of misfolded proteins, thereby mitigating ER stress. Dysregulation of VIMP or ERAD is associated with neurodegenerative diseases (e.g., Alzheimer’s), metabolic disorders, and certain cancers. Antibodies targeting VIMP are essential tools for studying ERAD mechanisms, protein quality control, and disease pathology. They enable detection of VIMP expression, localization, and interactions in cellular and tissue models, aiding research on ER stress responses and therapeutic targeting of ERAD-related conditions.
These antibodies are widely used in Western blotting, immunoprecipitation, and immunofluorescence to explore VIMP’s role in cellular proteostasis and disease.
×
